Aripiprazole/sertraline

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by LilHelpa (talk | contribs) at 13:51, 18 July 2020 (typo). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Aripiprazole/sertraline
Combination of
SertralineSelective serotonin reuptake inhibitor
AripiprazoleAtypical antipsychotic
Clinical data
Other namesASC-01
Routes of
administration		By mouth
Legal status
Legal status

Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), and aripiprazole (Abilify), an atypical antipsychotic, which is under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] The drug combines serotonin reuptake inhibition and modulation of dopamine and serotonin receptors.[1] In July 2017, it was in preregistration in Japan for the treatment of MDD.[1]

See also

References

  1. ^ a b c http://adisinsight.springer.com/drugs/800039778

External links



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Aripiprazole/sertraline&oldid=968295885"